Dapoxetine

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Sexual Dysfunction

Conditions

Sexual Dysfunction, Ejaculation

Trial Timeline

Nov 1, 2004 → Aug 1, 2005

NCT ID

NCT00210613

About Dapoxetine

Dapoxetine is a phase 3 stage product being developed by Johnson & Johnson for Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00210613. Target conditions include Sexual Dysfunction, Ejaculation.

What happened to similar drugs?

3 of 8 similar drugs in Sexual Dysfunction were approved

Approved (3) Terminated (0) Active (5)

✅sildenafilPfizerApproved

✅AlfuzosinSanofiApproved

✅Levitra (Vardenafil, BAY38-9456) + PlaceboBayerApproved

🔄AVANAFIL + placeboSanofiPhase 3

🔄tibolone + estradiol-norethisteroneOrganonPhase 3

🔄Bremelanotide + PlaceboPalatin TechnologiesPhase 3

🔄BremelanotidePalatin TechnologiesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00210704	Phase 3	Completed	Mar 1, 2005	Jun 1, 2006	Erectile Dysfunction
NCT00229073	Phase 3	Completed	Dec 1, 2004	Oct 1, 2006	Erectile Dysfunction
NCT00210613	Phase 3	Completed	Nov 1, 2004	Aug 1, 2005	Sexual Dysfunction

Competing Products

18 competing products in Sexual Dysfunction

See all competitors

Product	Company	Stage	Hype Score
Gardasil Vaccine	Merck	Pre-clinical	26
sildenafil	Pfizer	Approved	43
sildenafil	Pfizer	Phase 2	35
CP-866,087 + CP-866,087 + CP-866,087 + Placebo	Pfizer	Phase 2	35
PF-00446687 + Placebo	Pfizer	Phase 2	35
Bremelanotide	Pfizer	Phase 2	35
Sildenafil 100 mg + Placebo	Pfizer	Phase 2	35
Alfuzosin	Sanofi	Approved	43
AVANAFIL + placebo	Sanofi	Phase 3	40
Levitra (Vardenafil, BAY38-9456) + Placebo	Bayer	Approved	40
Placebo + 0.5 mgTestosterone + 10 mg Buspirone	Brain Biotech	Phase 2	25
Placebo + Testosterone + Buspirone hydrochloride	Brain Biotech	Phase 2	25
Placebo + Sildenafil + Testosterone	Brain Biotech	Phase 2	25
tibolone + estradiol-norethisterone	Organon	Phase 3	34
Bremelanotide + Placebo	Palatin Technologies	Phase 3	30
bremelanotide	Palatin Technologies	Phase 2	25
Bremelanotide	Palatin Technologies	Phase 3	30
EVO100 + Placebo	Evofem Biosciences	Phase 3	30